Pacific Biosciences of California (PACB) said Thursday it has appointed Chris Smith, chief executive of NeoGenomics (NEO), to the board of directors, effective immediately.
Smith has extensive experience in the life sciences and healthcare industries and led growth and innovation at NeoGenomics in precision medicine, Pacific Biosciences said.
The company said David Meline is resigning from its board, effective immediately, after contributing to the company's strategy since 2023.
Shares of Pacific Biosciences were up 1.9% and NeoGenomics rose 2.8% in recent trading.
Price: 1.59, Change: +0.03, Percent Change: +1.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments